This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
1 - 3 June, 2027
Congress CenterBasel Switzerland

James Ernst, Ph.D.
Vice President, Development Sciences; Head of Protein Sciences & Technology at Xencor
Speaker

Profile

James Ernst, Ph.D., has over 20 years of experience in biomedical research, spanning roles as both a bench scientist and an R&D executive. He is currently Vice Preside of Development and head of Protein Sciences & Technology at Xencor Inc., where he leads programs from molecule discovery into clinical development.

Previously, he held leadership roles in Genentech Research & Early Development (gRED) Protein Sciences, contributing to both large- and small-molecule discovery efforts across oncology, immunotherapy, neuroscience, and metabolic disease.

Dr. Ernst earned his Ph.D. in Biophysical Chemistry from Yale University and completed postdoctoral training at Stanford University School of Medicine. He also serves as Vice President of the Board of Directors of The Antibody Society.

Agenda Sessions

  • Dual Pathway Blockade in IBD: Discovery and Characterization of XmAb412, a High-Potency TL1A × IL-23 Bispecific Antibody

    09:20
  • Co-Chair’s Remarks

    08:55